

**ANNOUNCEMENT FOR THE OPENING OF AN INTERNATIONAL SELECTION TENDER
PROCEDURE FOR DOCTORATE HIRING OF DECREE-LAW NO. 57/2016 OF 29 AUGUST,
AMENDED BY LAW 57/2017 OF 19 JULY**

Code: **Researcher/RJEC/Ipatimup/P9/3/08092109/2021**

1. The meeting of the Board of Directors of IPATIMUP deliberated the opening of an international selection tender for 1 vacancy of doctorate to perform duties of scientific research in the scientific area of **BIostatistics**, under a work contract with non-fixed term under the Portuguese labor Law in order to perform duties, as researcher within the project with the reference POCI-01-0145-FEDER-028772 and the title “Glycans in autoimmunity. Impact in Systemic Lupus Erythematosus pathogenesis and treatment.” at Ipatimup, financed by FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT - Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior

2. Project's summary

Systemic Lupus Erythematosus(SLE) is a prototype autoimmune disease that remains a major clinical challenge. The mechanisms underlying the global loss of self-tolerance are still elusive and SLE remains a chronic, disabling and life-threatening condition. These clinical concerns led us to set this proposal of which the main goal is to assess whether an alteration of the cellular glycosylation signature is a yet uncovered factor underlying the loss of immunetolerance in SLE.

The immune system is tightly controlled by glycosylation, through the addition of carbohydrates (glycans) to proteins. We found that patients with Inflammatory Bowel Disease (IBD) exhibit a deficiency in branched glycans on mucosal T lymphocytes associated with T cell hyperactivity and disease severity. Interestingly, our exploratory results in lupus nephritis from SLE patients showed an altered expression of cellular glycosylation. The evidences in IBD together with our data in SLE raise the following questions: Can changes in glycans profile of cells contribute to the activation of innate and adaptive immune response in SLE?

3. Applicable Legislation

Decree-Law no. 57/2016 of 29 August, amended by Law 57/2017 of 19 July, which approved the doctorate hiring regime destined to stimulate scientific and technological employment for all knowledge areas (RJEC)

Labour Code, Law no. 7/2009 of 12 February, on its current draft

Regulatory Decree Nr 11-A / 2017, of 29th December

INSTITUTO
DE INVESTIGAÇÃO
E INOVAÇÃO
EM SAÚDE
UNIVERSIDADE
DO PORTO

Rua Alfredo Allen, 208
4200-135 Porto
Portugal
+351 220 408 800
info@i3s.up.pt
www.i3s.up.pt

4. Pursuant to article 13 of RJEC, the **tender selection** panel shall be formed by:

Salomé Soares de Pinho (President); Joana Gaifem (vogal1), Ângela Fernandes (vogal2)

5. **Workplace** can be fully/partially remote (online) or presential at Ipatimup-i3S, Rua de Alfredo Allen, 208, Porto, depending on the candidate preference and agreement with the PI.

6. Monthly remuneration to be paid is the remuneration set by subheading a) nr.1 article 15 of RJEC and article nr 2 of the Regulatory Decree nr. 11-A/2017, corresponding to level 33 of the Single Salary Table, approved by Order no. 1553-C/2008 of December 31st, i.e. 2.128,34 Euros., with the category of Junior Researcher.

7. Any national, foreign and stateless candidate(s) who hold a **doctorate degree in Biostatistics, Mathematics or related** scientific area and a scientific and professional curriculum whose profile is suited for the activity to be performed can submit their applications. In the event the doctorate degree was awarded by a foreign higher education institution, said degree must comply with the provisions of Decree-Law no. 341/2007 of 12 October, and all formalities established therein must be complied with at the signature of the contract.

8. **The tender admission specific requirements are:**

- PhD in Biostatistics; Mathematics or in related fields.
- Proven experience in statistical analysis; big data analysis in the scope of biomedical sciences.
- Capacity to collect, analyze, and summarize the data collected during a specific biological research and draw conclusions in the areas of medicine/autoimmunity.
- Preferred experience using Stata, SAS (including macros and SQL) and/or other statistical software such as R and SPSS.
- Competent in conducting longitudinal analyses in large samples.
- Excellent knowledge of statistical methods and its application in biomedical sciences.
- Effective communication skills with scientific investigators about design, data analysis, and results of clinical trials/research studies as well as translation of findings to lay public audiences.
- Availability to start the functions in the project from the 15th of October 2021 onwards, with a maximum duration of 2 months.

9. Pursuant to article 5 of RJEC, selection is to be made based on candidate scientific and curricular career evaluation.

10. Scientific and curricular career evaluation focuses on relevance, quality and up-to-dateness:

- a) of scientific and technological production in the last five years, deemed most relevant by the candidate;
- b) of research activities, applied or based on practical work, developed in the last five years, deemed most impactful by the candidate;
- c) of knowledge extension and dissemination activities developed in the last five years, namely under the scope of the promotion of culture and scientific practices, deemed most relevant by the candidate.

11. The five-year period mentioned above can be extended by the panel, if requested by the candidate, whenever the suspension of scientific activities is reasoned by socially protected grounds like paternity leave, long-term serious illness, and other legal situations of unavailability to work.

12. Evaluation criteria are the following:

Scientific career and laboratorial/in silico experience in the field of research (50%)

Scientific and technological production pertinent to the research area (40%)

Interview (10%)

13. The panel will interview candidates obtaining more than 80% in the remaining selection criteria, aimed to obtain clarifications and details of CV data and additional information.

14. Candidate final classification system shall be given based on a scale 0-20.

15. The panel shall deliberate by means of roll-call vote justified under adopted and disclosed selection criteria, with no abstentions allowed.

16. Minutes of panel meetings shall be executed and shall include a summary of all occurrences of said meeting, as well as of all votes casted by the members and respective reasoning, and shall be provided to candidates whenever required.

17. After selection criteria application, the panel shall prepare a sorted list of approved candidates and respective classification.

18. Panel's decision shall be validated by the leader of the institution, within no less of two working days counted from the following day of the publication of the sorted list of approved candidates and respective classification. The leader of the institution is also in charge of deciding about the hiring.

19. Application formalization:

INSTITUTO
DE INVESTIGAÇÃO
E INOVAÇÃO
EM SAÚDE
UNIVERSIDADE
DO PORTO

Rua Alfredo Allen, 208
4200-135 Porto
Portugal
+351 220 408 800
info@i3s.up.pt
www.i3s.up.pt

19.1 Applications are formalized upon application sent to the President of the Panel, including announcement identification, full name, residence and contact address, including email address and telephone.

19.2 Applications shall include all supported documents encompassed by section 7 and 8 for tender admission, namely:

- a) Certificate or diploma copy;
- b) Curriculum vitae, detailed and structured pursuant to sections 9 and 11;
- c) Other documentation relevant for the evaluation of qualifications in a related scientific area;
- d) Brief description of the most relevant scientific activities of the last 5 years (1/2 or 1 page maximum), according to article 5(2) of RJEC and point 9 of this announcement.

19.3 Candidates shall submit their application files and supporting documentation, in a digital form, in PDF format, from the 8th September 2021 to the 21th September 2021, through the link:

<https://dozer.i3s.up.pt/applicationmanagement/#/addapplications/ResearcherRJECIpatimupP93080921092021>

20. All candidates who formalize their applications in an improper way or fail to prove the requirements imposed by this tender are excluded from admission. In case of doubt, the panel is entitled to request any candidate to present further documentation supporting their statements.

21. False statements provided by the candidates shall be punished by law.

22. Both admitted and excluded candidate list and final classification list shall be published in the website of the Institute and the selected candidate shall be notified by email.

23. This tender is exclusively destined to fill this specify vacancy and can be terminated at any time until approval of final candidate list, expiring with the respective occupation of said vacancy.

24. Non-discrimination and equal access policy: Ipatimup actively promotes a non-discrimination and equal access policy, wherefore no candidate can be privileged, benefited, impaired or deprived of any rights whatsoever, or be exempt of any duties based on their ancestry, age, sex, sexual preference, marital status, family and economic conditions, instruction, origin or social conditions, genetic heritage, reduced work capacity, disability, chronic illness, nationality, ethnic origin or race, origin territory, language, religion, political or ideological convictions and union membership.

25. Pursuant to Decree-Law no. 29/2001 of 3 February, disabled candidates shall be preferred in a situation of equal classification, and said preference supersedes any legal preferences. Candidates must declare, on their honour, their respective disability degree, type of disability and communication/expression means to be used during selection period on their application form, under the regulations above.

26. The panel has approved this announcement in meeting held on 06/09/2021.